CVS Health delivered a solid third quarter with revenue reaching a record $103 billion (up 8%) and adjusted EPS surging 47% to $1.60. For the third consecutive quarter, the company raised its full-year 2025 adjusted EPS guidance to $6.55-$6.65, driven by significant margin recovery in its Aetna insurance segment and better-than-expected performance in retail pharmacy. However, results were marred by a massive $5.7 billion goodwill impairment charge in the Health Care Delivery segment (Oak Street Health) due to a strategic decision to slow clinic growth. The PBM business faced near-term headwinds from legacy contract guarantees, prompting a reduction in segment guidance, though management remains bullish on the long-term shift to the transparent 'TrueCost' model. Looking ahead to 2026, management projects mid-teens EPS growth off a normalized baseline, signaling confidence in the sustainability of the turnaround.
| Metric | Value | Change |
|---|---|---|
| Total Revenue | $103 Billion | +8% |
| Adjusted EPS | $1.60 | +47% |
| Adjusted Operating Income | $3.5 Billion | +36% |
| Medical Benefit Ratio (MBR) | 92.8% | -240 bps |
| Cash Flow from Operations (YTD) | $7.2 Billion | N/A |
| Retail Pharmacy Script Share | 28.9% | Increase |
| Health Services Revenue | $49 Billion | +11% |
| Health Care Delivery Revenue | N/A | +25% (ex-ACO) |
The Aetna turnaround is gaining significant traction, evidenced by a 240 basis point year-over-year improvement in the Medical Benefit Ratio (MBR) to 92.8%. Management attributes this to 'premium deficiency reserves,' favorable prior period development, and improved government business performance. This validates the strategic focus on disciplined underwriting and plan design, positioning the segment for 'another year of meaningful margin improvement' in 2026.
CVS is aggressively pivoting its PBM strategy toward the 'TrueCost' model, which guarantees net drug costs and offers transparency. While legacy 'market basket' contracts caused a $240 million guidance reduction this quarter, management views TrueCost as the 'model of the future' that will drive long-term value. The successful retention of clients and $6 billion in new wins during a 'disrupted' selling season suggests the market values this evolution.
The Retail Pharmacy (PCW) segment is stabilizing faster than anticipated, now expected to grow 3% for the year—a significant swing from initial expectations of a 5% decline. This resilience is driven by market share gains (28.9% share), the integration of Rite Aid assets, and the 'CostVantage' initiative. Management's confidence suggests the retail headwinds are abating, supporting the broader enterprise thesis.
A major strategic shift occurred in Health Care Delivery, where CVS is prioritizing profitability over growth by slowing Oak Street clinic expansion. This resulted in a $5.7 billion impairment but signals a 'prudent' capital allocation strategy. Management insists value-based care remains 'critical,' but the focus is now on 'fair and equitable contracts' and closing underperforming clinics to fix margins.
Management is actively leveraging macro-political winds, specifically supporting the Trump administration's focus on lowering brand drug prices. By aligning with government efforts to tackle 'inequitable pricing strategies,' CVS aims to create a 'new lower ceiling price' in the U.S., which they believe will benefit their PBM negotiation leverage and consumer sentiment.
The $5.7 billion goodwill impairment charge within the Health Care Delivery segment is a massive red flag regarding the Oak Street Health acquisition. It indicates that the initial growth thesis and valuation assumptions were flawed, forcing a strategic reset to slow clinic openings. This casts doubt on management's M&A judgment and the immediate profitability of their value-based care expansion.
The PBM segment (Health Services) saw adjusted operating income decline 7% year-over-year, driven by 'legacy market basket' contracts that failed to account for shifting drug mix (specifically GLP-1s and autoimmune drugs). This highlights a vulnerability in their existing contract structure and creates a financial overhang as they transition to new pricing models over the next few years.
Medical membership declined by 445,000 year-over-year, driven by losses in Individual Exchange and Medicare lines. While Aetna's margins are improving, the shrinking member base suggests competitive pressures or pricing disconnects that could limit long-term top-line growth in the core insurance business.
Elevated medical cost trends remain a persistent threat. Management noted that trends were 'modestly favorable' relative to expectations but still 'elevated across all products.' The 100 basis point negative impact from provider liabilities (dating back to 2018) and worsening risk adjustment data suggests reserve adequacy and pricing accuracy are ongoing battles.
Cash flow guidance, while raised to $7.5-$8.0 billion, implies a significant backend load for Q4. With $2.3 billion in cash at the parent and ongoing dividend payments ($2.6 billion YTD), the balance sheet remains a focal point, especially given the massive non-cash impairment charge which, while not hitting cash flow, signals asset value destruction.
Overall: Management displayed a tone of disciplined confidence and 'urgency' throughout the call. While acknowledging significant challenges such as the Oak Street impairment and PBM headwinds, executives emphasized a 'beat and raise' track record and the successful execution of their turnaround strategy. The demeanor shifted from defensive regarding the impairment to highly optimistic when discussing Aetna's recovery and the future of the PBM model.
Confidence: HIGH - Management raised guidance for the third straight time and provided a specific 2026 growth outlook (mid-teens), signaling strong visibility into their performance. They used definitive language regarding the Aetna recovery and retail market share gains, while maintaining a 'prudent' outlook on macro factors.
$6.55 to $6.65 (Raised from $6.30 to $6.40)
At least $397 Billion
$7.5 Billion to $8.0 Billion
Mid-teens percentage growth off normalized baseline
At least $7.1 Billion (Decreased from prior)
~$2.72 Billion (Increased)
Hedging & Uncertainty: Management frequently used qualifiers like 'prudent,' 'cautious,' and 'disciplined' to frame their outlook, particularly regarding medical cost trends and the PBM transition. For example, Brian Newman stated, 'This outlook continues to maintain a thoughtful and prudent view on medical cost trends.' However, they were less hedged on the turnaround success, using stronger verbs like 'delivered,' 'achieved,' and 'building momentum.' The use of 'expect' was high, but often backed by specific data points (e.g., 'expect over 81% of our Medicare Advantage members will be in plans rated 4 stars or higher'). The hedging increased slightly when discussing 2026 specifics, deferring formal guidance to the Investor Day, yet they provided a concrete 'mid-teens' growth target, reducing uncertainty.
We are building momentum across the enterprise and feel a growing excitement about the opportunities ahead. - J. Joyner, CEO
The reasons to believe in this business have not changed, but the marketplace is evolving and we are adapting our strategy. - J. Joyner, CEO
We are incredibly proud to say we are the best running pharmacy in the country. - Prem Shah, President of Pharmacy & Consumer Wellness
We recognize the importance of establishing credible commitments and expect to continue this philosophy as we establish future financial targets. - Brian Newman, CFO
This is the third consecutive quarter where we both exceeded and raised guidance. - J. Joyner, CEO
We are taking a cautious outlook in light of the broader pressures across the industry. - Brian Newman, CFO
Analyst Sentiment: Analysts were highly inquisitive about the mechanics of the PBM headwinds, specifically distinguishing between the impact of the new 'TrueCost' model versus legacy 'market basket' contracts. There was also skepticism regarding the sustainability of the retail turnaround and the specific losses within the Oak Street business.
Management Responses: Management was well-prepared and defensive in a constructive manner, particularly Prem Shah regarding the PBM. They clarified that headwinds were from legacy contracts, not TrueCost. They were transparent about the Oak Street impairment but reframed it as a strategic move to ensure long-term profitability. They provided specific details on the 2026 baseline calculation to reassure investors about the growth trajectory.
Deep dive into PBM economics and the specific drivers of the $240 million guidance reduction (GLP-1 mix, autoimmune drugs).
Clarification on the $5.7 billion impairment and the future path to profitability for Oak Street Health.
Discussion on the sustainability of the Retail/PCW margin improvement and the impact of the Rite Aid asset acquisition.
Analysis of the Aetna medical benefit ratio and the impact of one-time items like provider liabilities.
Inquiries into the 2026 baseline adjustment, specifically the removal of the $0.45 per share in prior year reserve development.
CVS Health is successfully executing a complex turnaround, evidenced by three consecutive quarters of raised guidance and a massive 47% EPS beat in Q3. The Aetna recovery is real, driven by better underwriting and Stars ratings, while the Retail segment is showing unexpected resilience. However, the $5.7 billion goodwill impairment on Oak Street Health is a significant stain on management's capital allocation track record and introduces uncertainty about the growth profile of their provider assets. Furthermore, the PBM segment is navigating a difficult transition between legacy and new pricing models, creating a near-term earnings headwind. While the 2026 outlook of mid-teens growth is encouraging, the reliance on 'one-time' reserve development to bridge the gap and the operational complexity of integrating diverse business units warrant a cautious stance. The stock is suitable for investors seeking value and turnaround potential, but the risk of execution errors remains high until the PBM transition stabilizes and Oak Street proves its profitability.
Management expressed strong support for the Trump administration's focus on lowering brand drug prices and addressing global price disparities. They believe this regulatory environment will help lower the 'ceiling price' in the U.S., allowing PBMs to negotiate better net costs and relieving the financial burden on consumers.
The company noted slower growth in GLP-1s than expected, partly due to compounding volumes not returning to the benefit as anticipated. This shift in drug mix negatively impacted PBM rebate guarantees, highlighting the sensitivity of their business model to the utilization trends of this specific high-cost drug category.
The Inflation Reduction Act (IRA) continues to drive revenue growth in the Medicare Part D program. Additionally, despite CMS raising cut points for Stars ratings, CVS maintained its leadership position, suggesting their scale provides a defensive moat against regulatory tightening in government business.